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Anticoagulation for
Atrial Fibrillation Ablation
What Is the Optimal Strategy?*
Bradley P. Knight, MD
Chicago, Illinois
Regardless of the approach to perioperative anticoagulation
used, patients need to have a normal or nearly normal state
of coagulation during surgery, so some increase in the
risk of thromboembolism is unavoidable.
—Kearon and Hirsh, 1997 (1)
Catheter ablation procedures are increasingly being per-
formed for patients with medically refractory, symptomatic
atrial fibrillation (AF). Because these procedures involve
ablation in the systemic circulation and often conversion
from AF to sinus rhythm, they are associated with a
significant risk of thromboembolism. Therefore, many
strategies are used during an ablation procedure to reduce
the risk of stroke, including the use of intracardiac echocar-
diography, irrigated ablation electrodes, and aggressive an-
ticoagulation (2).
See page 1168
In addition, several anticoagulation strategies have
emerged to manage patients before and immediately after an
ablation procedure for AF (Tables 1 and 2). When AF
ablation began, it was standard practice to interrupt warfarin
and “bridge” patients with low molecular weight heparin
(LMWH) (Option #1 in Tables 1 and 2). Unfortunately,
this approach was associated with a high rate of vascular
access site complications. Most centers switched to half-
dose LMWH and saw less bleeding, without a higher risk of
stroke (Option #2 in Tables 1 and 2). The LMWH can be
given soon after sheaths are pulled or held until the next
morning while the patient is given intravenous unfraction-
ated heparin. Regardless of the dose, however, administra-
tion of LMWH is costly, unpleasant for many patients, and
often not covered by insurance companies.
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relevant to the contents of this paper to disclose.The notion that patients need to have normal coagulation
properties to undergo invasive procedures (1) has been
challenged recently. It has now been demonstrated that
several cardiac procedures, including device implantation (3)
and coronary interventions (4), can be performed safely
without interruption of warfarin, an approach that may be
preferable to bridging with LMWH. In addition, left atrial
ablation has been shown to be safe when performed in
patients taking therapeutic warfarin, at experienced centers
(Option #3 in Tables 1 and 2). In a series of 2,600 patients
with AF who underwent ablation on warfarin, Di Biase et
al. (5) found in 2010 that the combination of an open
irrigation ablation catheter and periprocedural therapeutic
anticoagulation with warfarin was associated with no strokes
or transient ischemic attacks, without an increase in the risk
of pericardial effusion or other bleeding complications.
Further evidence that such an approach is safe came from a
study by Latchamsetty et al. (6) that showed that if
pericardial tamponade did occur, it was not more severe or
difficult to manage in the presence of therapeutic anticoag-
ulation with warfarin.
Despite clear demonstration that catheter ablation can be
performed safely without stopping warfarin, this approach
has not been adopted by all centers. Electrophysiologists
who work at low-volume centers or who are just beginning
to perform AF ablation are understandably cautious and
concerned that if a catastrophic complication were to occur,
it could be more life-threatening when the patient is
anticoagulated with warfarin. There is also a concern that a
practice that deviates from the conventional practices fol-
lowed for most other surgeries and procedures would be
difficult to defend if a complication were to occur. There-
fore, there has been an interest in taking advantage of the
benefits of the newer, shorter acting oral anticoagulants such
as dabigatran, a direct thrombin inhibitor, around the time
of catheter ablation for AF.
In this issue of the Journal, Lakkireddy et al. (7) com-
pared the bleeding and stroke rates in patients undergoing
AF ablation while on uninterrupted warfarin with those
patients managed periprocedurally with dabigatran (Option #3
vs. Option #4 in Table 2). The investigators found a higher
incidence of bleeding and pericardial effusions in patients
treated with dabigatran and no difference in the rate of
thromboembolism compared with warfarin.
At first this paper appears to suggest that dabigatran has
no role periprocedurally in patients undergoing AF ablation.
In fact, many physicians who participated in this study now
convert their patients who are taking dabigatran to warfarin
before an AF ablation procedure. However, it is important
to note that dabigatran may still have a role around the time
of an AF ablation. In the study by Lakkireddy et al.,
dabigatran was not stopped until the morning of the
procedure and was restarted 3 h after sheaths were pulled.
Given that the half-life of dabigatran is 14 to 17 h, this
protocol is nearly equivalent to performing the procedure
d hepa
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there is arguably no standard of care on how to manage
dabigatran around the time of an ablation procedure, as
Lakkireddy et al. (7) acknowledge, the half-life of the drug
is long enough that the recommendations of the manufac-
turer are to stop it at least 1 to 2 days before invasive or
surgical procedures in patients with normal renal function
Approaches to Periprocedural Anticoagulation for Catheter AblationTable 1 Approaches to Periprocedural Anticoagulation for Cath
Option Day
#1 5 4 3 2 1 0 1 2 3
W* W W W W
H(L) L L L
#2 5 4 3 2 1 0 1 2 3
W* W W W W
H(L) ½L ½L ½L ½
#3 5 4 3 2 1 0 1 2 3
W W W W W W W W W
#4 5 4 3 2 1 0 1 2 3
D D D D D D† D D D
#5 5 4 3 2 1 0 1 2 3
D* D* D* H D D D
#6 5 4 3 2 1 0 1 2 3
D* D* D* H ½D ½D ½D
#7 5 4 3 2 1 0 1 2 3
R* R* R* H R R R
*Prescribed only for patients with CHADS2 score 0. †Hold morning dose before procedure. Give
AF  atrial fibrillation; Coags  coagulation parameters; D  dabigatran; H  unfractionate
 warfarin.
Approaches to Periprocedural Anticoagulation for Catheter AblationTable 2 Approaches to Periprocedural Anticoagulation for Cath
Option Day
#1 5 4 3 2 1 0 1 2 3
W W W W W
L L L H(L) L L L
#2 5 4 3 2 1 0 1 2 3
W W W W W
L L L H(L) ½L ½L ½L ½
#3 5 4 3 2 1 0 1 2 3
W W W W W W W W W
#4 5 4 3 2 1 0 1 2 3
D D D D D D† D D D
#5 5 4 3 2 1 0 1 2 3
D* D* D* H D D D
#6 5 4 3 2 1 0 1 2 3
D* D* D* H ½D ½D ½D
#7 5 4 3 2 1 0 1 2 3
R R R R R R R R R*Prescribed only for patients with CHADS2 score 0. †Hold morning dose before procedure. Give dose 3
Abbreviations as in Table 1.and to consider longer times when complete hemostasis may
be required.
Alternative anticoagulation approaches that might still
take advantage of the benefits of dabigatran compared with
warfarin would be to hold the dabigatran for 1 to 2 days
before the ablation, give intravenous heparin during and
after the procedure, and resume the dabigatran the follow-
aroxysmal AFAblation of Paroxysmal AF
Pros Cons
5 Normalizes coags for procedure Full-dose L increases bleeding
after procedure
Inconvenient/expensive for patient
W
L
5 Normalizes coags for procedure
Reduces access site bleeding
Inconvenient/expensive for patient
W
½L
5 Avoids fluctuations in coags
Simple/convenient for patients
Safe at experienced centers
Could worsen outcome of
any bleeding/tamponade
Deviates from standard surgical
practices
Difficult to predict whether INR
too high on day of procedure
W
5 Avoids fluctuations
Simple/convenient for patients
Increases bleeding/complications (7)
D
5 Normalizes coags for procedure Could increase post-procedure
bleeding complicationsD
5 Normalizes coags for procedure May not provide enough
post-procedure anticoagulationD
5 Potential antidote available
R
h after hemostasis is achieved post-procedure.
rin; INR  international normalized ratio; L  low-molecular-weight heparin; R  rivaroxaban;
ersistent AFAblation of Persistent AF
Pros Cons
5 Normalizes coags for procedure Full-dose L increases bleeding
after procedure
Inconvenient/expensive for patient
W
L
5 Normalizes coags for procedure
Reduces access site bleeding
Inconvenient/expensive for patient
W
½L
5 Avoids fluctuations in coags
Simple/convenient for patients
Evidence-based
Could worsen outcome of
any bleeding/tamponade
Deviates from standard surgical
practices
Difficult to predict whether INR
too high on day of procedure
W
5 Avoids fluctuations
Simple/convenient for patients
Increases bleeding/complications (7)
D
5 Normalizes coags for procedure Could increase post-procedure
bleeding complicationsD
5 Normalizes coags for procedure May not provide enough
post-procedure anticoagulationD
5 Potential antidote available
Rof Peter
4
W
L
4
W
L
4
W
4
D
4
D
4
D
4
R
dose 3of Peter
4
W
L
4
W
L
4
W
4
D
4
D
4
D
4
Rh after hemostasis is achieved post-procedure.
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nonrandomized study by Winkle et al. (8) found no pre-
procedural or intraprocedural thromboembolic episodes or
bleeding in 34 patients who were managed periprocedurally
with dabigatran. In the Winkle et al. (8) study, dabigatran
was held for 36 h before the procedure, half-dose LMWH
was given after the procedure, and dabigatran was restarted
22 h after the procedure. It might also be reasonable to use
half the usual dose of dabigatran (or the 110-mg dose where
it is available), extrapolating from the lessons learned
regarding the benefits of lower doses of LMWH post-
procedure (Option #6 in Tables 1 and 2). Other options
include using newer oral anticoagulants other than dabiga-
tran, such as rivaroxaban (9), a direct Xa inhibitor (Option
#7 in Tables 1 and 2). Rivaroxaban was recently approved
for use for AF, has a shorter half-life than dabigatran, and
appears to be reversible with prothrombin complex concen-
trates (10) if bleeding or tamponade were to occur.
Lakkireddy et al. (7) should be commended for pooling
such a large number of patients from multiple centers to
examine the role of dabigatran around the time of AF
ablation. Based on their study, it appears that AF ablation
should not be performed on nearly uninterrupted dabiga-
tran, as it was used in this study. However, other approaches
that capitalize on the advantages of the new oral anticoag-
ulants must continue to be explored.
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